B
Bull
Bull · 25%CERO
$10.66
Scenario price
$0.095
-0.090 (-94.69%)At close
Loading chart…
- High
- 0.404
- Open
- 0.338
- VWAP
- 0.19
- Vol
- 114.68M
- Mkt Cap
- —
- Low
- 0.085
- Amount
- 22.33M
- EV/EBITDA, TTM
- 0.00
CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what the Company refers to as Chimeric Engulfment Receptor T cells (CER-T). Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.
Valuation Metrics
The current forward P/E ratio for CERo Therapeutics Holdings Inc (CERO) is -0.02, compared to its 5-year average forward P/E of -0.04.
Alphio AI Price Scenarios for CERO
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding CERO
Events Timeline
News
8.508-31NewsfilterSRX Global Acquires CERo Debt to Support R&D
9.006-15NewsfilterCER-1236 Clinical Trial Update
- 9.003-30Newsfilter
CERo Therapeutics Advances CER-1236 Clinical Trial in Hematologic Malignancies
- 9.002-04Newsfilter
CERo Therapeutics Presents CER-1236 Clinical Data at ASTCT Meeting
9.001-07GlobenewswireCERo Therapeutics Expands Clinical Trial Focus, Reports 61-Day Transfusion-Free Interval
CERO FAQ — answered by Alphio AI
CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what the Company refers to as Chimeric Engulfment Receptor T cells (CER-T). Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.